1	Inhibition	Inhibition	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	cyclooxygenase-2	cyclooxygenase-2	_	_	_	_	_	_	_
4	expression	expression	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	4-trifluoromethyl	4-trifluoromethyl	_	_	_	_	_	_	_
7	derivatives	derivative	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	salicylate	salicylate	_	_	_	_	_	_	_
10	,	,	_	_	_	_	_	_	_
11	triflusal	triflusal	_	_	_	_	_	_	_
12	,	,	_	_	_	_	_	_	_
13	and	and	_	_	_	_	_	_	_
14	its	its	_	_	_	_	_	_	_
15	deacetylated	deacetylate	_	_	_	_	_	_	_
16	metabolite	metabolite	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	2-hydroxy-4-trifluoromethylbenzoic	2-hydroxy-4-trifluoromethylbenzoic	_	_	_	_	_	_	_
19	acid	acid	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	therapeutic	therapeutic	_	_	_	_	_	_	_
3	potential	potential	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	drugs	drug	_	_	_	_	_	_	_
6	that	that	_	_	_	_	_	_	_
7	block	block	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	induction	induction	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	cyclooxygenase-2	cyclooxygenase-2	_	_	_	_	_	_	_
12	has	have	_	_	_	_	_	_	_
13	been	be	_	_	_	_	_	_	_
14	emphasized	emphasize	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	When	when	_	_	_	_	_	_	_
2	two	two	_	_	_	_	_	_	_
3	4-trifluoromethyl	4-trifluoromethyl	_	_	_	_	_	_	_
4	salicylate	salicylate	_	_	_	_	_	_	_
5	derivatives	derivative	_	_	_	_	_	_	_
6	[	[	_	_	_	_	_	_	_
7	2-acetoxy-4-trifluoromethyl-benzoic	2-acetoxy-4-trifluoromethyl-benzoic	_	_	_	_	_	_	_
8	acid	acid	_	_	_	_	_	_	_
9	(	(	_	_	_	_	_	_	_
10	triflusal	triflusal	_	_	_	_	_	_	_
11	)	)	_	_	_	_	_	_	_
12	and	and	_	_	_	_	_	_	_
13	its	its	_	_	_	_	_	_	_
14	deacetylated	deacetylate	_	_	_	_	_	_	_
15	metabolite	metabolite	_	_	_	_	_	_	_
16	2-hydroxy-4-trifluoromethylbenzoic	2-hydroxy-4-trifluoromethylbenzoic	_	_	_	_	_	_	_
17	acid	acid	_	_	_	_	_	_	_
18	(	(	_	_	_	_	_	_	_
19	HTB	HTB	_	_	_	_	_	_	_
20	)	)	_	_	_	_	_	_	_
21	]	]	_	_	_	_	_	_	_
22	were	be	_	_	_	_	_	_	_
23	compared	compare	_	_	_	_	_	_	_
24	with	with	_	_	_	_	_	_	_
25	aspirin	aspirin	_	_	_	_	_	_	_
26	and	and	_	_	_	_	_	_	_
27	sodium	sodium	_	_	_	_	_	_	_
28	salicylate	salicylate	_	_	_	_	_	_	_
29	as	as	_	_	_	_	_	_	_
30	cyclooxygenase-2	cyclooxygenase-2	_	_	_	_	_	_	_
31	(	(	_	_	_	_	_	_	_
32	COX-2	cox-2	_	_	_	_	_	_	_
33	)	)	_	_	_	_	_	_	_
34	inhibitors	inhibitor	_	_	_	_	_	_	_
35	,	,	_	_	_	_	_	_	_
36	we	we	_	_	_	_	_	_	_
37	observed	observe	_	_	_	_	_	_	_
38	that	that	_	_	_	_	_	_	_
39	in	in	_	_	_	_	_	_	_
40	bacterial	bacterial	_	_	_	_	_	_	_
41	lipopolysaccharide-activated	lipopolysaccharide-activated	_	_	_	_	_	_	_
42	human	human	_	_	_	_	_	_	_
43	blood	blood	_	_	_	_	_	_	_
44	,	,	_	_	_	_	_	_	_
45	triflusal	triflusal	_	_	_	_	_	_	_
46	,	,	_	_	_	_	_	_	_
47	aspirin	aspirin	_	_	_	_	_	_	_
48	,	,	_	_	_	_	_	_	_
49	and	and	_	_	_	_	_	_	_
50	HTB	HTB	_	_	_	_	_	_	_
51	,	,	_	_	_	_	_	_	_
52	but	but	_	_	_	_	_	_	_
53	not	not	_	_	_	_	_	_	_
54	sodium	sodium	_	_	_	_	_	_	_
55	salicylate	salicylate	_	_	_	_	_	_	_
56	,	,	_	_	_	_	_	_	_
57	inhibited	inhibit	_	_	_	_	_	_	_
58	COX-2-mediated	cox-2-mediated	_	_	_	_	_	_	_
59	prostaglandin	prostaglandin	_	_	_	_	_	_	_
60	E2	e2	_	_	_	_	_	_	_
61	(	(	_	_	_	_	_	_	_
62	PGE2	pge2	_	_	_	_	_	_	_
63	)	)	_	_	_	_	_	_	_
64	production	production	_	_	_	_	_	_	_
65	(	(	_	_	_	_	_	_	_
66	IC50	ic50	_	_	_	_	_	_	_
67	=	=	_	_	_	_	_	_	_
68	0.16	0.16	_	_	_	_	_	_	_
69	,	,	_	_	_	_	_	_	_
70	0.18	0.18	_	_	_	_	_	_	_
71	,	,	_	_	_	_	_	_	_
72	0.39	0.39	_	_	_	_	_	_	_
73	,	,	_	_	_	_	_	_	_
74	and	and	_	_	_	_	_	_	_
75	>10	>10	_	_	_	_	_	_	_
76	mM	mm	_	_	_	_	_	_	_
77	,	,	_	_	_	_	_	_	_
78	respectively	respectively	_	_	_	_	_	_	_
79	)	)	_	_	_	_	_	_	_
80	.	.	_	_	_	_	_	_	_

1	However	however	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	only	only	_	_	_	_	_	_	_
4	triflusal	triflusal	_	_	_	_	_	_	_
5	and	and	_	_	_	_	_	_	_
6	aspirin	aspirin	_	_	_	_	_	_	_
7	inhibited	inhibit	_	_	_	_	_	_	_
8	purified	purify	_	_	_	_	_	_	_
9	COX-2	cox-2	_	_	_	_	_	_	_
10	enzyme	enzyme	_	_	_	_	_	_	_
11	.	.	_	_	_	_	_	_	_

1	To	to	_	_	_	_	_	_	_
2	test	test	_	_	_	_	_	_	_
3	this	this	_	_	_	_	_	_	_
4	apparent	apparent	_	_	_	_	_	_	_
5	discrepancy	discrepancy	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	we	we	_	_	_	_	_	_	_
8	realized	realize	_	_	_	_	_	_	_
9	that	that	_	_	_	_	_	_	_
10	HTB	HTB	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	triflusal	triflusal	_	_	_	_	_	_	_
13	(	(	_	_	_	_	_	_	_
14	but	but	_	_	_	_	_	_	_
15	neither	neither	_	_	_	_	_	_	_
16	aspirin	aspirin	_	_	_	_	_	_	_
17	nor	nor	_	_	_	_	_	_	_
18	salicylate	salicylate	_	_	_	_	_	_	_
19	)	)	_	_	_	_	_	_	_
20	produced	produce	_	_	_	_	_	_	_
21	a	a	_	_	_	_	_	_	_
22	concentration-dependent	concentration-dependent	_	_	_	_	_	_	_
23	inhibition	inhibition	_	_	_	_	_	_	_
24	of	of	_	_	_	_	_	_	_
25	COX-2	cox-2	_	_	_	_	_	_	_
26	protein	protein	_	_	_	_	_	_	_
27	expression	expression	_	_	_	_	_	_	_
28	in	in	_	_	_	_	_	_	_
29	peripheral	peripheral	_	_	_	_	_	_	_
30	human	human	_	_	_	_	_	_	_
31	mononuclear	mononuclear	_	_	_	_	_	_	_
32	cells	cell	_	_	_	_	_	_	_
33	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	observation	observation	_	_	_	_	_	_	_
3	was	be	_	_	_	_	_	_	_
4	further	further	_	_	_	_	_	_	_
5	confirmed	confirm	_	_	_	_	_	_	_
6	in	in	_	_	_	_	_	_	_
7	a	a	_	_	_	_	_	_	_
8	rat	rat	_	_	_	_	_	_	_
9	air	air	_	_	_	_	_	_	_
10	pouch	pouch	_	_	_	_	_	_	_
11	model	model	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	vivo	vivo	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	in	in	_	_	_	_	_	_	_
16	which	which	_	_	_	_	_	_	_
17	both	both	_	_	_	_	_	_	_
18	aspirin	aspirin	_	_	_	_	_	_	_
19	and	and	_	_	_	_	_	_	_
20	triflusal	triflusal	_	_	_	_	_	_	_
21	inhibited	inhibit	_	_	_	_	_	_	_
22	PGE2	pge2	_	_	_	_	_	_	_
23	production	production	_	_	_	_	_	_	_
24	(	(	_	_	_	_	_	_	_
25	ID50	id50	_	_	_	_	_	_	_
26	=	=	_	_	_	_	_	_	_
27	18.9	18.9	_	_	_	_	_	_	_
28	and	and	_	_	_	_	_	_	_
29	11.4	11.4	_	_	_	_	_	_	_
30	mg/kg	mg/kg	_	_	_	_	_	_	_
31	p.o.	p.o.	_	_	_	_	_	_	_
32	,	,	_	_	_	_	_	_	_
33	respectively	respectively	_	_	_	_	_	_	_
34	)	)	_	_	_	_	_	_	_
35	but	but	_	_	_	_	_	_	_
36	only	only	_	_	_	_	_	_	_
37	triflusal-treated	triflusal-treated	_	_	_	_	_	_	_
38	animals	animal	_	_	_	_	_	_	_
39	showed	show	_	_	_	_	_	_	_
40	a	a	_	_	_	_	_	_	_
41	decrease	decrease	_	_	_	_	_	_	_
42	in	in	_	_	_	_	_	_	_
43	COX-2	cox-2	_	_	_	_	_	_	_
44	expression	expression	_	_	_	_	_	_	_
45	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	different	different	_	_	_	_	_	_	_
3	behavior	behavior	_	_	_	_	_	_	_
4	may	may	_	_	_	_	_	_	_
5	be	be	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	at	at	_	_	_	_	_	_	_
8	least	least	_	_	_	_	_	_	_
9	in	in	_	_	_	_	_	_	_
10	part	part	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	due	due	_	_	_	_	_	_	_
13	to	to	_	_	_	_	_	_	_
14	the	the	_	_	_	_	_	_	_
15	ability	ability	_	_	_	_	_	_	_
16	of	of	_	_	_	_	_	_	_
17	HTB	HTB	_	_	_	_	_	_	_
18	and	and	_	_	_	_	_	_	_
19	triflusal	triflusal	_	_	_	_	_	_	_
20	to	to	_	_	_	_	_	_	_
21	block	block	_	_	_	_	_	_	_
22	the	the	_	_	_	_	_	_	_
23	activation	activation	_	_	_	_	_	_	_
24	of	of	_	_	_	_	_	_	_
25	the	the	_	_	_	_	_	_	_
26	transcription	transcription	_	_	_	_	_	_	_
27	factor	factor	_	_	_	_	_	_	_
28	nuclear	nuclear	_	_	_	_	_	_	_
29	factor-kappaB	factor-kappab	_	_	_	_	_	_	_
30	to	to	_	_	_	_	_	_	_
31	a	a	_	_	_	_	_	_	_
32	higher	high	_	_	_	_	_	_	_
33	extent	extent	_	_	_	_	_	_	_
34	than	than	_	_	_	_	_	_	_
35	aspirin	aspirin	_	_	_	_	_	_	_
36	and	and	_	_	_	_	_	_	_
37	sodium	sodium	_	_	_	_	_	_	_
38	salicylate	salicylate	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

1	Thus	thus	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	in	in	_	_	_	_	_	_	_
4	addition	addition	_	_	_	_	_	_	_
5	to	to	_	_	_	_	_	_	_
6	inhibiting	inhibit	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	COX-2	cox-2	_	_	_	_	_	_	_
9	activity	activity	_	_	_	_	_	_	_
10	at	at	_	_	_	_	_	_	_
11	therapeutic	therapeutic	_	_	_	_	_	_	_
12	concentrations	concentration	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	triflusal	triflusal	_	_	_	_	_	_	_
15	is	be	_	_	_	_	_	_	_
16	able	able	_	_	_	_	_	_	_
17	to	to	_	_	_	_	_	_	_
18	block	block	_	_	_	_	_	_	_
19	through	through	_	_	_	_	_	_	_
20	its	its	_	_	_	_	_	_	_
21	metabolite	metabolite	_	_	_	_	_	_	_
22	HTB	htb	_	_	_	_	_	_	_
23	the	the	_	_	_	_	_	_	_
24	expression	expression	_	_	_	_	_	_	_
25	of	of	_	_	_	_	_	_	_
26	new	new	_	_	_	_	_	_	_
27	enzyme	enzyme	_	_	_	_	_	_	_
28	,	,	_	_	_	_	_	_	_
29	and	and	_	_	_	_	_	_	_
30	hence	hence	_	_	_	_	_	_	_
31	the	the	_	_	_	_	_	_	_
32	resumption	resumption	_	_	_	_	_	_	_
33	of	of	_	_	_	_	_	_	_
34	PGE2	pge2	_	_	_	_	_	_	_
35	synthesis	synthesis	_	_	_	_	_	_	_
36	.	.	_	_	_	_	_	_	_

1	Triflusal	Triflusal	_	_	_	_	_	_	_
2	and	and	_	_	_	_	_	_	_
3	HTB	HTB	_	_	_	_	_	_	_
4	may	may	_	_	_	_	_	_	_
5	exert	exert	_	_	_	_	_	_	_
6	beneficial	beneficial	_	_	_	_	_	_	_
7	effects	effect	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	processes	process	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	which	which	_	_	_	_	_	_	_
12	de	de	_	_	_	_	_	_	_
13	novo	novo	_	_	_	_	_	_	_
14	COX-2	cox-2	_	_	_	_	_	_	_
15	expression	expression	_	_	_	_	_	_	_
16	is	be	_	_	_	_	_	_	_
17	involved	involve	_	_	_	_	_	_	_
18	and	and	_	_	_	_	_	_	_
19	,	,	_	_	_	_	_	_	_
20	in	in	_	_	_	_	_	_	_
21	a	a	_	_	_	_	_	_	_
22	broader	broad	_	_	_	_	_	_	_
23	sense	sense	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	in	in	_	_	_	_	_	_	_
26	pathological	pathological	_	_	_	_	_	_	_
27	situations	situation	_	_	_	_	_	_	_
28	in	in	_	_	_	_	_	_	_
29	which	which	_	_	_	_	_	_	_
30	genes	gene	_	_	_	_	_	_	_
31	under	under	_	_	_	_	_	_	_
32	nuclear	nuclear	_	_	_	_	_	_	_
33	factor-kappaB	factor-kappab	_	_	_	_	_	_	_
34	control	control	_	_	_	_	_	_	_
35	are	be	_	_	_	_	_	_	_
36	up-regulated	up-regulate	_	_	_	_	_	_	_
37	.	.	_	_	_	_	_	_	_

